Broad based screen of possible biomarkers. p53 is included here.
Breast and Gynecologic Cancers Research
The overall goal of this project application for the EDRN set-aside funds is to focus our collaborative efforts to identify p53 mutation-specific antibody biomarkers in breast, prostate, and ovarian cancer. P53-specific gene mutations are frequent in multiple cancer types. Of the common solid tumors, p53 mutations have been identified in 50% of lung and ovarian cancers, 45% of colon cancers, 20% of breast cancers, and 10-30% of prostate cancers (The p53 Mutation Handbook, T. Soussi, http://p53/free/fr). The most common mutations vary from cancer to cancer, with 50 point mutations covering the 10 most common mutations for all major solid tumors
1.B. Project Objectives
Aim 1: Generation of NAPPA protein microarrays expressing the fifty most common p53 point mutations for solid tumors as well as deletion constructs of p53.
Aim 2: Identify p53 mutation-specific antibodies in a test set of breast, prostate, and ovarian cancer patient sera.
a. Using test sera from patients with prostate, ovarian, and breast cancers, identify patient sera that contain anti-p53 antibodies.
b. Using p53-antibody-positive sera from patients, screen the p53 mutation microarray to identify mutation-specific and domain-specific antibodies
c. Using p53-antibody-negative sera from patients, screen the p53 mutation microarray to identify mutation-specific antibodies
d. Determine the sensitivity and specificity of individual antibodies that distinguish patient sera from normal sera.
e. Determine if mutation-specific antibodies can distinguish tumor types.
Various including quantile regression, Fishers exact, binomial proportion and others. The methods are not yet fixed because we are still in discovery.
Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held October 15-16, 2015 on the NCI campus. More information will be available later this summer.